Do you use the same criteria for offering neoadjuvant chemotherapy in a lobular breast cancer as you would in ductal?   

HER2+ ILC is uncommon but can be seen in about 5% of ILC cancer cases. A retrospective review by MD Anderson suggested similar outcomes for HER2+ ILC vs IDC. (JCO 2012, ASCO Absract 612) I would confirm the HER2+ and low grade in this case, as that is discordant. As for regular ILC which is usually ...